Comparing Two Drugs for Leukaemia Treatment in Rats
Author Information
Author(s): D.J. Richel, L.P. Colly, E. Lurvink, R. Willemze
Primary Institution: University Hospital Leiden
Hypothesis
Is 5 aza-2-deoxycytidine more effective than arabinofuranosyl-cytosine in treating myelocytic leukaemia in rats?
Conclusion
5 aza-2-deoxycytidine is a more effective antileukaemic agent than arabinofuranosyl-cytosine in rats with myelocytic leukaemia.
Supporting Evidence
- Aza-dC increased median survival time significantly compared to ara-C.
- Aza-dC showed a dose-response relationship for doses up to 50mg/kg.
- Aza-dC did not affect cell cycle kinetics in the first 24 hours after exposure.
Takeaway
This study tested two drugs to see which one helps rats with leukaemia live longer. One drug worked much better than the other.
Methodology
The study used a survival study and flow cytometric analysis to compare the effects of the two drugs on leukaemic rats.
Limitations
The study was conducted in a rat model, which may not fully represent human responses.
Participant Demographics
Brown Norway rats with myelocytic leukaemia.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website